I'll suggest reading two writeups on VIC, https://www.valueinvestorsclub.com/
For me, I am mostly looking at bigger picture and downside protection. Plasma protein market will continue to grow for the foreseeable future. GRFS is in plasma protein oligopoly. Debt is being used to acquire smaller players in the market. The cost of debt is low, indicating no worries that company will not be able to debt/interest. I don't see a scenario where rev does not grow or margins suppress. The risk is that gene editing tech (CRISPR etc) makes plasma protein therapies obsolete, but that is really far in my opinion. Recent weakness in share price is due to debt and dividend cut. My time horizon and expectation is a double in 5 years.